Last reviewed · How we verify
BMS955176
At a glance
| Generic name | BMS955176 |
|---|---|
| Sponsor | ViiV Healthcare |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
- Fatigue
- Abnormal dreams
- Sleep disorder
- Diarrhoea
- Dry mouth
- Abdominal distension
- Night sweats
- Hypertension
- Thrombophlebitis
- Anogenital warts
- Nodule
Key clinical trials
- Study to Evaluate a HIV Drug for the Treatment of HIV Infection (PHASE2)
- Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults (PHASE2)
- Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults (PHASE2)
- Study on Effects of BMS-955176 on the Pharmacokinetics of Probe Substrates (PHASE1)
- Study of Combined Oral Contraceptive Effects in Female Subjects (PHASE1)
- Taste Properties of HIV Inhibitor (PHASE1)
- Study of the Absorption, Metabolism, and Route of Elimination of a Novel Class of Anti-HIV 1 Drugs (BMS-955176) in Humans. (PHASE1)
- Relative Bioavailability Study With BMS-955176 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BMS955176 CI brief — competitive landscape report
- BMS955176 updates RSS · CI watch RSS
- ViiV Healthcare portfolio CI